突变型p21 ras肽疫苗接种后胰腺癌患者免疫反应的特征分析
Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination.
作者信息
Gjertsen M K, Saeterdal I, Thorsby E, Gaudernack G
机构信息
Institute of Transplantation Immunology, National Hospital, University of Oslo, Norway.
出版信息
Br J Cancer. 1996 Dec;74(11):1828-33. doi: 10.1038/bjc.1996.638.
Abstract
This is a study of immune responses generated by mutant ras peptide vaccination of patients with pancreatic adenocarcinoma. Responding T cells from one patient were cloned and two CD4+ T-lymphocyte clones (TLC) specific for the 12 Val peptide and restricted by HLA-DR6 or DQ2 were obtained. These class II molecules have not previously been found to bind or present mutant ras peptides to T cells. The DR6-restricted TLC showed marked cytotoxicity against autologous target cells pulsed with the 12 Val peptide. Target cells pulsed with the control peptide were not killed. Responding T cells from another patient showed cross-reactivity towards the homologous ras peptides. Investigation by limiting dilution analysis (LDA) revealed different T-cell precursor frequencies for the immunising, mutant ras peptide (1:28000), compared with the normal ras peptide (1:110000).
摘要
这是一项关于胰腺腺癌患者接受突变型ras肽疫苗接种后产生的免疫反应的研究。从一名患者的反应性T细胞中进行克隆，获得了两个针对12缬氨酸肽且受HLA-DR6或DQ2限制的CD4+ T淋巴细胞克隆（TLC）。此前尚未发现这些II类分子能将突变型ras肽结合或呈递给T细胞。受DR6限制的TLC对用12缬氨酸肽脉冲处理的自体靶细胞表现出明显的细胞毒性。用对照肽脉冲处理的靶细胞未被杀死。另一名患者的反应性T细胞对同源ras肽表现出交叉反应性。通过有限稀释分析（LDA）研究发现，与正常ras肽（1:110000）相比，免疫用的突变型ras肽的T细胞前体频率不同（1:28000）。
相似文献
1
Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination.突变型p21 ras肽疫苗接种后胰腺癌患者免疫反应的特征分析
Br J Cancer. 1996 Dec;74(11):1828-33. doi: 10.1038/bjc.1996.638.
2
Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation.通过对一名患者进行突变型p21-ras（12Val）肽疫苗接种产生的细胞毒性CD4+和CD8+ T淋巴细胞，识别疫苗肽中存在的12Val依赖性嵌套表位，并杀死携带该突变的自体肿瘤细胞。
Int J Cancer. 1997 Sep 4;72(5):784-90. doi: 10.1002/(sici)1097-0215(19970904)72:5<784::aid-ijc14>3.0.co;2-9.
3
Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.胰腺癌中针对突变型p21 ras癌蛋白的天然T细胞反应。
Clin Cancer Res. 2006 Feb 15;12(4):1365-72. doi: 10.1158/1078-0432.CCR-05-1672.
4
Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.从用反映第12密码子突变的ras癌基因衍生肽免疫的患者中生成稳定的CD4 +和CD8 + T细胞系。
Cell Immunol. 1997 Dec 15;182(2):137-51. doi: 10.1006/cimm.1997.1224.
5
Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.针对携带K-ras p21突变表位的肿瘤细胞的细胞溶解性CD4+ T淋巴细胞的肽特异性激活。
Eur J Immunol. 1995 Sep;25(9):2588-97. doi: 10.1002/eji.1830250928.
6
[CD4+ T-cell immunity and Ab responses to mutant ras protein in pancreas and colon cancer patients].[胰腺癌和结肠癌患者中CD4 + T细胞免疫及对突变型ras蛋白的抗体反应]
Zhonghua Zhong Liu Za Zhi. 1996 May;18(3):173-6.
7
HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.通过接种辅助性T细胞表位诱导产生的HLA - A3限制性突变型ras特异性细胞毒性T淋巴细胞。
J Mol Med (Berl). 2003 Jan;81(1):43-50. doi: 10.1007/s00109-002-0390-y. Epub 2002 Nov 13.
8
[Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].[用突变型K-ras肽脉冲处理的树突状细胞诱导的胰腺癌特异性免疫]
Zhonghua Yi Xue Za Zhi. 2008 Jul 22;88(28):1956-60.
9
Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model.使用经基因改造以表达肿瘤抗原的自发性爱泼斯坦-巴尔病毒淋巴母细胞系作为癌症疫苗：以胰腺癌中的突变型p21 ras癌基因作为模型
Hum Gene Ther. 2002 May 1;13(7):815-27. doi: 10.1089/10430340252898993.
10
CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients.胰腺癌和结肠癌患者针对突变型ras蛋白的CD4 + T细胞免疫
Cancer Res. 1995 Jul 15;55(14):2984-7.
引用本文的文献
1
Neo-antigen specific cancer vaccines for acute lymphoblastic leukemia-challenges, opportunities, and future directions.用于急性淋巴细胞白血病的新抗原特异性癌症疫苗——挑战、机遇与未来方向
Cancer Immunol Immunother. 2025 Jun 23;74(8):248. doi: 10.1007/s00262-025-04107-y.
2
In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene census.基于癌症基因名录中功能错义突变的肿瘤抗原的计算机预测。
Oncoimmunology. 2012 Nov 1;1(8):1281-1289. doi: 10.4161/onci.21511.
3
Trials of gene therapy for pancreatic carcinoma.胰腺癌基因治疗试验。
Curr Gastroenterol Rep. 2005 Jun;7(3):165-9. doi: 10.1007/s11894-005-0028-7.
4
Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer.移码突变衍生肽作为遗传性和自发性结直肠癌中的肿瘤特异性抗原
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13255-60. doi: 10.1073/pnas.231326898. Epub 2001 Oct 30.
5
Lack of evidence for MHC-unrestricted (atypical) recognition of mucin by mucinous pancreatic tumour-reactive T-cells.缺乏黏液性胰腺肿瘤反应性T细胞对黏蛋白进行MHC非限制性（非典型）识别的证据。
Br J Cancer. 2000 Feb;82(3):691-701. doi: 10.1054/bjoc.1999.0982.
6
The potential for gene therapy in pancreatic cancer.胰腺癌基因治疗的潜力。
Int J Pancreatol. 1999 Aug;26(1):5-21. doi: 10.1385/IJGC:26:1:5.
本文引用的文献
1
Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study.晚期胰腺癌患者的离体RAS肽疫苗接种：一项I/II期研究的结果
Int J Cancer. 1996 Feb 8;65(4):450-3. doi: 10.1002/(SICI)1097-0215(19960208)65:4<450::AID-IJC10>3.0.CO;2-E.
2
T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction.针对p21 ras衍生肽的T细胞克隆：其精细特异性和HLA限制的特征
Eur J Immunol. 1993 Mar;23(3):754-60. doi: 10.1002/eji.1830230328.
3
Tumor antigens recognized by T lymphocytes.被T淋巴细胞识别的肿瘤抗原。
Annu Rev Immunol. 1994;12:337-65. doi: 10.1146/annurev.iy.12.040194.002005.
4
Binding of ras oncogene peptides to purified HLA-DQ(alpha 1*0102,beta 1*0602) and -DR(alpha,beta 1*0101) molecules.ras癌基因肽与纯化的HLA-DQ（α1*0102，β1*0602）和-DR（α，β1*0101）分子的结合。
Scand J Immunol. 1994 Jun;39(6):607-12. doi: 10.1111/j.1365-3083.1994.tb03420.x.
5
p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp).一名结直肠癌患者的p21-ras肽特异性T细胞反应。CD4+和CD8+ T细胞识别对应于一种常见突变（13甘氨酸→天冬氨酸）的肽段。
Int J Cancer. 1994 Jan 2;56(1):40-5. doi: 10.1002/ijc.2910560108.
6
CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13-->Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation.来自一名结肠癌患者的CD8 + T细胞，对一种源自突变型p21-Ras的肽（Gly13→Asp）具有特异性，对携带相同突变的癌细胞系具有细胞毒性。
Cancer Immunol Immunother. 1995 Mar;40(3):165-72. doi: 10.1007/BF01517348.
7
Overlapping epitopes encompassing a point mutation (12 Gly-->Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells.包含p21 ras中一个点突变（12甘氨酸→精氨酸）的重叠表位可被HLA - DR、- DP和 - DQ限制性T细胞识别。
Eur J Immunol. 1993 Oct;23(10):2687-91. doi: 10.1002/eji.1830231045.
8
Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein.在Ras蛋白中鉴定出两个细胞毒性T淋巴细胞识别表位。
J Exp Med. 1993 May 1;177(5):1493-8. doi: 10.1084/jem.177.5.1493.
9
Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.通过用合成肽脉冲的自体抗原呈递细胞免疫在人黑色素瘤中原位诱导抗原特异性细胞溶解T细胞。
Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):8078-82. doi: 10.1073/pnas.92.17.8078.
10
T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA.包含p21 ras第61位突变热点位置的T细胞表位。ras肽与HLA结合的多反应性。
Eur J Immunol. 1994 Feb;24(2):410-4. doi: 10.1002/eji.1830240221.
Zotero 插件